Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-175 in Advanced Malignancies with TP53 R175H Mutation
NCT05877599Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2023
- Primary completion
- Jul 2029
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NT-175 in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), colorectal carcinoma (CRC) and 6 more, sponsored by AstraZeneca. Primary endpoints: Safety of NT-175 in participants with unresectable, advanced, and/or metastatic solid tumours at 28 days, Preliminary anti-tumour activity of NT-175 in participants with unresectable, advanced, and/or metastatic solid tumours at 24 months and 1 more. Started Jul 2023; status: recruiting.
02
Drugs
NT-175
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)colorectal carcinoma (CRC)pancreatic adenocarcinoma (PDAC)breast cancer
Beyond the preview
Go deeper on NCT05877599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05877599.